Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. (TCRT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
tcrt · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Alaunos Therapeutics, Inc. (TCRT) measures how much investors pay for each dollar of the company's trailing earnings. TCRT's current PE ratio of N/A is calculated by dividing its stock price of $2.02 by its TTM earnings per share of -$2.11.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Alaunos Therapeutics, Inc.You TCRT | $5M | N/A | — | -$2.11 |
 Addex Therapeutics Ltd ADXN | $4M | N/A | — | -$7.20 |
 AIM ImmunoTech Inc. AIM | $2M | N/A | — | -$8.62 |
 Cyclerion Therapeutics, Inc. CYCN | $13M | N/A | — | -$1.09 |
 Impact BioMedical Inc. IBO | $7M | N/A | — | -$0.38 |
 Pasithea Therapeutics Corp. KTTA | $4M | N/A | — | -$2.91 |
 Polyrizon Ltd. PLRZ | $14M | N/A | — | -$2.07 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.14 | — | |
2024-12-31 FY2024 | — | $-2.92 | — | |
2023-12-31 FY2023 | — | $-21.97 | — | |
2022-12-31 FY2022 | — | $-26.07 | — | |
2021-12-31 FY2021 | — | $-55.10 | — | |
2020-12-31 FY2020 | — | $-57.22 | — | |
2019-12-31 FY2019 | — | $-105.21 | — | |
2018-12-31 FY2018 | — | $-55.52 | — | |
2017-12-31 FY2017 | — | $-59.50 | — | |
2016-12-31 FY2016 | — | $-190.15 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Alaunos Therapeutics, Inc. (TCRT) measures how much investors pay for each dollar of the company's trailing earnings. TCRT's current PE ratio of N/A is calculated by dividing its stock price of $2.02 by its TTM earnings per share of -$2.11.
Frequently asked questions
TCRT pe ratio · 6 questionsTCRT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.02 and TTM EPS of -$2.11. Data sourced from Financial Modeling Prep via TCRT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Alaunos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09